Posts tagged “Novartis”

Updated April 22, 2014

Premium Lock GSK-Novartis deals slide show: How they change GSK

Drug giants GlaxoSmithKline and Novartis each offered investors online presentations that spell out graphically how the deals announced Tuesday will affect each company. Here's a look at three key slides from the GSK presentation.

GSK's proposed new vaccine portfolio GSK's proposed new vaccine portfolio

January 14, 2014

Premium Lock Square worth $5B?; SAS lands big deal; PayPal's new service; Merck stock jumps; BlackBerry's new sales chief

Bulldog In our Bulldog blog's tech and life science news update: Square offers shares at $135 each; SAS signs Europe's leading drugstore chain; PayPal testing new service; Merck shares jump on drug news; BlackBerry names new sales chief and lands $250M in investment.

January 9, 2014

Premium Lock Report: Novartis looks to deal vaccine, animal health businesses to Merck

Novartis reportedly is in negotiations with fellow drug giant Merck about a $10 billion asset swap that would include the Novartis human vaccines and animal health businesses. Novartis operates a huge vaccine in Holly Springs and is building an R&D center in RTP.

Novartis plant in Holly Springs Novartis plant in Holly Springs

Updated October 22, 2013

Premium Lock SAS ranks No. 2, Quintiles No. 18 in global Great Place to Work list

Several technology and life science firms with a major presence in North Carolina crack the top 25 in the annual World's Best Multinational Workplaces ranking. NetApp, Cisco, Google, Microsoft and Novartis all make the list.

World's Best Multinational Workplaces World's Best Multinational Workplaces

October 9, 2013

Premium Lock Novartis' North Carolina vaccine team takes up arms

Employees rolled up their sleeves at the $1 billion Novartis Holly Springs vaccine manufacturing facility this week and joined the global throngs marking a revolution in the fight against flu.

Flucelvax package photo, courtesy of Novartis. Flucelvax package photo, courtesy of Novartis.

Updated October 9, 2013

Premium Lock Drug giant Novartis to launch research lab in RTP

Novartis, which operates a huge vaccine manufacturing facility in Holly Springs, is going to hire up to 100 people to staff a new research and development lab in Research Triangle Park. Some jobs also will be moved to RTP from Massachusetts.

Inside the Novartis plant Inside the Novartis plant

Updated August 19, 2013

Premium Lock Chairman: Novartis, which has huge plant in Holly Springs, to review business units

International drug maker Novartis will start a strategic review of its units as early as next week and would consider a $10 billion purchase among options for bolstering the business, says new Chairman Joerg Reinhardt.

Novartis plant in Holly Springs Novartis plant in Holly Springs

Updated July 17, 2013

Premium Lock Novartis slashes ex-chairman's golden parachute to $6M from $78M

Novartis CEO Joe Jimenez, left, and former Chairman Daniel Vasella Novartis AG has cut former Chairman Daniel Vasella's payout to less than a tenth of the original $78 million, a sum that had helped galvanize support for a Swiss referendum on limiting executive pay.

Updated July 17, 2013

Premium Lock As blood pressure generic fails to materialize, Novartis ups full-year guidance

Novartis Europe's biggest drugmaker says it expects to lose $2.7 billion in sales to generic competition this year, 23 percent less than it previously forecast, as it continues to benefit from Ranbaxy Laboratories's failure to market a copycat version of the Diovan hypertension drug.

June 28, 2013

Premium Lock SAS, Quintiles slip on Europe 'Best Companies' list

Great Place To Work logo Several high-tech and life science firms based in North Carolina or who have a large presence here crack the "Best Multinationals" to work for list in Europe. But several of them also drop somewhat from the 2012 list.

February 22, 2013

Premium Lock Novartis chairman may keep working with firm as a consultant

Daniel Vasella Daniel Vasella, who is stepping down as chairman of international drug firm Novartis and decided not to accept a $78 million non-compete agreement, is now talking with the company about a consulting role.

February 19, 2013

Premium Lock No $78M golden parachute deal for Novartis chairman

Daniel Vasella Daniel Vasella, who is stepping down as chairman of international drug firm Novartis, cancels his $78 million agreement to not work for rival drug makers.

January 24, 2013

Premium Lock Will Novartis vaccine plant in Holly Springs be on auction block?

As drug maker Novartis goes through a change at the top with Chairman Daniel Vasella stepping down, investors celebrate the move and call for the company to spin off some assets such as its vaccine business.

Novartis' plant in Holly Springs Novartis' plant in Holly Springs

January 23, 2013

Premium Lock Novartis chairman stepping down; top Bayer exec to replace him

Novartis Daniel Vasella, the controversial Swiss executive who created drugmaker Novartis, unexpectedly said he will leave the board after 17 years, handing over to Bayer AG's top health-care executive.

Updated November 21, 2012

Premium Lock FDA approves Novartis vaccine made at Holly Springs plant

The U.S. Food and Drug Administration gives approval for a seasonal influenza vaccine produced at Novartis' new, huge production facility in Holly Springs.

Novartis plant in Holly Springs Novartis plant in Holly Springs

October 25, 2012

Premium Lock Nebraska drug plant problems plaguing Novartis

Novartis Novartis, which operates a large production plant as well as a research and development operation in Holly Springs, N.C., says shutdown Nebraska plant is hurting its consumer sales.

August 29, 2012

Premium Lock Novartis smoker's cough drug beats GSK's Advair in trial

Lung disease Patients taking Novartis's QVA149 were able to expel more air from their lungs in one second than those receiving Glaxo's best-selling Advair after 26 weeks of treatment, according to a summary of data from a trial.

August 29, 2012

Premium Lock Novartis experimental heart-failure drug shows promise

Heart research  If successful, LCZ696 would be the first drug for patients with preserved ejection fraction, a condition in which the organ's ventricles still pump out more than 40 percent of the blood that comes in, but the atrium chamber fails to supply enough blood to the ventricle to meet the body's needs. The condition, which mainly affects women, accounts for about half of all heart failure patients.

August 7, 2012

Premium Lock Novartis funds $20M cancer facility at U. of Pennsylvania

Cancer research  In exchange for the funding, the drug giant gains rights to the university's cancer technology that utilizes manipulated immune system stem cells.

June 19, 2012

Premium Lock Novartis, GSK win big biodefense center contracts

Pandemic Novartis along with Duke and NCSU will create a center for biodefense and to combat pandemic influenza in Holly Springs under a $60 million contract with the U.S. Department of Health and Human Services. GSK will work with Texas A&M on a $176 million deal.

Techwire Inside Partners
The Skinny: A Blog by Rick Smith